MEDITECH(SH:603990)2025-01-17 11:35Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between -190 million and -250 million yuan, indicating a loss compared to the previous year[5]. - The estimated net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between -280 million and -340 million yuan for 2024[5]. - The total profit for 2023 was -261.99 million yuan, with a net profit attributable to shareholders of the parent company at -269.42 million yuan[5]. - The company reported a loss per share of -0.88 yuan for the previous year[6]. - The performance forecast is based on preliminary calculations and has not been audited[5]. - The forecast period for the 2024 performance is from January 1, 2024, to December 31, 2024[5]. - There are no major uncertainties that could affect the accuracy of this performance forecast[8]. Business Strategy - The primary reason for the expected loss is the significant decline in sales prices due to a mismatch in supply and demand in the photovoltaic industry, leading to reduced operational capacity and substantial losses in the photovoltaic business[7]. - The company plans to divest its photovoltaic business subsidiaries, focusing on the development of its core medical business after the sale[9]. Investment Risks - The company emphasizes the importance of investors being aware of investment risks related to the preliminary data provided[9].